Use of Funds
$15M funding to launch three tests and begin to revenue
Category
Amount
Sales & Marketing
$3,000,000
Product Development
$2,500,000
IPO Costs
$2,250,000
Laboratory Costs
$1,585,000
Legal & Regulatory
$1,110,000
C-Suite & Administrative Personnel
$1,210,000
Laboratory Personnel
$374,000
Manufacturing Ramp Up
$1,200,000
Subtotal
$13,229,000
Contingency
$1,771,000
Total
$15,000,000
To date: IP development of StromaGenesis funded using ~$10MM in Grants [NIH/DOD/State Funds]
CEO Richard Pestell, MD acquired the Algorithm [asset] from CytoDyn 6/22 [BDO Valuation $9.6MM]
CEO Richard Pestell, MD acquired additional assets on 6/22 [~$1.5MM expended]
These funds have provided verification of the algorithm and Clinical Trial materials supported by 36 publications.
100 East Lancaster Ave
Room R234
Wynnewood, Pennsylvania 19096
